NEWS CENTER
SCROLL
Jan 01, 2025
01/ 01
Rona Therapeutics Appoints Alex M. DePaoli, MD, as Chief Medical Officer and Executive Vice President of Translational Research
Nov 15, 2024
15/ 11
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions
Oct 24, 2024
24/ 10
Rona Therapeutics Unveils Extrahepatic siRNA Delivery Data in CNS Utilizing Receptor-Mediated Endocytosis and Novel siRNA Design At 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Jul 26, 2024
26/ 07
Rona Therapeutics announced that the self-developed APOC3 siRNA drug， RN0361，received approval for a Phase I clinical trial application in Australia
Jul 19, 2024
19/ 07
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Jun 13, 2024
13/ 06
Rona Therapeutics and EnnovaBio Pharmaceuticals Published Late Breaker Poster of First-in-class Liver Targeted CIDEB siRNA for MASH in EASL Congress 2024
EXPLORER MORE
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...